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a b s t r a c t
The size of aerosol particles prior to, and during, inhalation inﬂuences the site of deposition within the
lung. As such, a detailed understanding of the hygroscopic growth of an aerosol during inhalation is nec-
essary to accurately model the deposited dose. In the ﬁrst part of this study, it is demonstrated that the
aerosol produced by a nebulizer, depending on the airﬂows rates, may experience a (predictable) wide
range of relative humidity prior to inhalation and undergo dramatic changes in both size and solute con-
centration. A series of sensitive single aerosol analysis techniques are then used to make measurements
of the relative humidity dependent thermodynamic equilibrium properties of aerosol generated from
four common nebulizer formulations. Measurements are also reported of the kinetics of mass transport
during the evaporation or condensation of water from the aerosol. Combined, thesemeasurements allow
accurate prediction of the temporal response of the aerosol size prior to and during inhalation. Speciﬁ-
cally, we compare aerosol composed of pure saline (150mMsodium chloride solution in ultrapurewater)
with two commercially available nebulizer products containing relatively low compound doses: Breath®,
consisting of a simple salbutamol sulfate solution (5mg/2.5mL; 1.7mM) in saline, and Flixotide® Nebules,
consisting of amore complex stabilizedﬂuticasonepropionate suspension (0.25mg/mL; 0.5mMin saline.
A mimic of the commercial product Tobi© (60mg/mL tobramycin and 2.25mg/mL NaCl, pH 5.5–6.5) is
also studied, which was prepared in house. In all cases, the presence of the pharmaceutical was shown
to have a profound effect on the magnitude, and in some cases the rate, of the mass ﬂux of water to and
from the aerosol as compared to saline. These ﬁndings provide physical chemical evidence supporting
observations fromhuman inhalation studies, and suggest that using the growth dynamics of a pure saline
aerosol in a lung inhalation model to represent nebulizer formulations may not be representative of the
osoliactual behavior of the aer
. Introduction
For nearly a century, nebulizers have been used to administer
edication to the lungs and account for ∼13% of all inhaler retail
ales in Europe as of 2008 (Lavorini et al., 2011). During this time,
he use of the respiratory tract for drug delivery has proven highly
uccessful for treating not only diseases of the lung, such as deliv-
ring bronchodilators to treat asthma (Johnson, 1989), but also in
he treatment of systemic diseases, such as delivering insulin to
reat diabetes (Dubus and Luc, 2003;Watts et al., 2008). In diseases
f the lung, and to a lesser extent systemic diseases, the efﬁcacy
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of the drug can be correlated to the site of drug deposition and
delivery (Labiris and Dolovich, 2003). For this reason, the ability
to effectively model the eventual site of drug deposition as a func-
tion of the composition, size distribution and phase of the nascent
aerosol could prove to be advantageous in the design of nebulizer
formulations and devices.
Although the importance of the aerodynamic diameter of an
aerosol particle in determining the likelihood and site of deposition
within the lung iswell appreciated (Carvalhoet al., 2011), the roleof
the hygroscopic growth of the aerosol, when produced with a neb-
ulizer, remains a contentious issue. While the hygroscopic growth
of ﬁne and ultra-ﬁne aerosol (diameter <1m) during inhalation is
widely recognized to occur (Asgharian, 2004; Kim et al., 2012), the
Open access under CC BY license.degree of hygroscopic growth of ‘coarse’ respirable aerosol (diam-
eter >1m) is speculated to be minimal (Dennis, 2009; Finlay,
1998; Finlay and Smaldone, 1998). Given that the aerosol gen-
erated by many nebulizers has an aerodynamic size distribution
urnal of Pharmaceutics 463 (2014) 50–61 51
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Fig. 1. (A) Two common airﬂows found in commercially available nebulizers. (B) A
hypothetical representation of changes to relative humidity (%) during a wet nebu-
lization inhalationprocess: (i) represents theaerosol generationprocess, (ii) denotes
aerosol transport phase from the nebulization chamber to the mouthpiece (2 s),
(iii) represents onset of aerosol inhalation and (iv) depicts the period aerosol res-
idence in the lower respiratory tract. Points (v) and (vi) represent two different
exhalation scenarios: (v) describes a relatively rapid exhalation based on tidal
breathing and (vi) represents a hypothetical scenario in which the breath is held for
∼10 s prior to exhalation. In both scenarios it is assumed that the RH% will remain
at near saturation until exhalation is completed. This representation is based onA.E. Haddrell et al. / International Jo
oncentrated in the coarse mode (Kallstrom et al., 2008), this
ssumption suggests that nebulized aerosol will not signiﬁcantly
hange size during inhalation, regardless of composition. There are
our commonly held reasons thatmay support the assumption that
ygroscopic growth can be neglected. The ﬁrst reason is that the
arge number of droplets per unit volume in a nebulized aerosol
ill stabilize individual particles against hygroscopic size changes.
he large evaporating mass of water from the aerosol on nebu-
ization is sufﬁcient to ensure the relative humidity (RH) remains
igh and, thus, the aerodynamic diameter of all the droplets in
he nebulized aerosol will remain approximately constant prior to
nhalation (Dennis, 2009).
The second reason hygroscopic aerosol growth is sometimes
hought to beminimal during inhalation is that the RH range that a
ebulized aerosol experiences during inhalation is considered to be
inimal (Dennis, 2009). As with the ﬁrst reason, this is attributed
o the large number of droplets in the aerosol which are believed
o sustain the RH at or above 99.5%. When the nebulized airﬂow
ncounters any change in RH, the high RH is maintained by a
et mass ﬂux of water from the large number of droplets present
nto the gas phase (Ferron et al., 1997). This, however, is not the
ase (Prokop et al., 1995), and a series of recent publications have
xplored this process further (Krajnik et al., 2009; Nerbrink et al.,
003; Zhou et al., 2005). In these studies, the aerodynamic diame-
er of droplets in a nebulized aerosol is measured as a function of
he ambient RH of the air that is mixed with the nebulized aerosol
rior to inhalation. The inﬂuence of the ambient RH on the size
istribution was found to be very much dependent on the path-
ay of the airﬂows through the nebulizer. When the only airﬂow
n the system passes through the nebulized region (Fig. 1A(i)), also
nown as a breath enhanced nebulizer (e.g. Pari LC+ (Pari GmbH,
tarnberg, Germany)), the RH throughout the system remains at or
ear saturation (Berg et al., 2007). This results from the ambient air
ecoming saturated in the nebulization region. As a result, for these
ypes of nebulizers the degree of size change of the aerosol prior to
nhalation is expected, and observed (Nerbrink et al., 2003), to be
inimal. When the pathway of the ambient airﬂow instead meets
he nebulized airﬂow at a T-junction (Fig. 1A(ii)) the volume of air
nd amount of time that the aerosol and ambient air spend mixing
re controlled by the breathing rate of the patient and the breathing
ircuit design. For these systems, it was consistently observed that
he RH of the ambient air had a signiﬁcant and direct effect on the
erodynamic diameter of the aerosol exiting the nebulizer prior to
mmediate inhalation and the degree of the size change was found
o be a function of the ambient RH (Krajnik et al., 2009; Nerbrink
t al., 2003; Zhou et al., 2005).
The third reason thathygroscopic growth is sometimesassumed
o be minimal during inhalation is the absence of any measure-
ents that allow direct access to the rapid and signiﬁcant changes
n aerosol particle size that can occur at the near-saturation RH
nd elevated temperature characteristic of the respiratory tract.
peciﬁcally, measurements of both the magnitude and rate of
ondensational growth for aerosols generated from nebulizer for-
ulations have not been possible until recently (Davies et al.,
012b). Without such data, the rate of growth of hygroscopic
erosol has been assumed to be that of pure saline (Xi et al., 2011),
recluding any quantitative assessment of the role of hygroscopic
rowth of coarse nebulized aerosols during inhalation and the
ependence on aerosol composition. The approach proposed here
s to exploit recently developed single droplet analysis techniques
o measure the time dependence of the mass ﬂux to and from an
erosol of known composition as a function of the RH. An improved
nderstanding of the mass ﬂux from a single droplet will enable
arameterization of amore accurate condensational growthmodel
ompared to previous reports. This newparameterizationwill then
e used to predict the dynamic changes in aerosol size during aexperimental data from a combination of sources (Ferron, 1994; Martonen et al.,
1982; Morrow, 1986).
variety of hypothetical inhalation scenarios. One example is
depicted in Fig. 1B for a constant output jet nebulizer with a T-
junction.
The fourth reason that hygroscopic growth is often ignored is
the assumption that there is insufﬁcient water vapor in the lung to
fully supply and sustain the growth of a large number of droplets
in a nebulized aerosol. As a result, the amount of growth that is
possible within the lungs is considered to be limited. It should be
noted that the ﬁrst, second and fourth issues are connected; either
the aerosol is able to buffer the change in ambient/lung RHor not; if
it is unable to buffer the change the changes in the RH is then large
enough to cause a signiﬁcant change in the aerodynamic size. In
this study, each of these issues will be explored, and the potential
importance of hygroscopic growth of nebulized pharmaceuticals in
the estimation of dose, both overall and targeted, will be discussed.
The thermodynamic and kinetic factors governing the capacity
of aerosols containing active pharmaceutical ingredients in saline
solutions to undergo hygroscopic growth during inhalation remain
ill-deﬁned (Chan et al., 1994; Martonen et al., 1982). To enhance
our understanding of the response of aerosol particle size to rapid
changes in humidity for typical nebulizer product formulations,
two different commercially available nebulizer formulations
are compared with 150mM sodium chloride (NaCl) solution in
ultrapure water (referred to as saline in this study) to determine
if the low drug content, either in solution or suspension form,
inﬂuences hygroscopic growth proﬁles in nebulized products.
Saline is the most commonly used vehicle in nebulizer solutions
5 urnal of Pharmaceutics 463 (2014) 50–61
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Fig. 2. (A) Experimental setup to measure the RH of an airﬂow mixed with nebu-
lized water. (B) The predicted limit of the RH in an airﬂow based solely on the mass
of water nebulized. (C) The actual RH in an airﬂow when no secondary airﬂow is
applied. The light gray bar indicates saturation region of the probe. (D) The actual
RH of an airﬂow when a secondary airﬂow is controlled and introduced to the neb-
ulizer. Green triangles are the RH measurements, the red line is the expected RH
based solely on the mass of water that was nebulized, and the gray area is the error2 A.E. Haddrell et al. / International Jo
nd was selected as a reference. The two commercially available
ebulizer products chosen to represent low dose formulations
ere: Breath®, and Flixotide® Nebules.
Secondly, formulations of high dose nebulizer solutions are
valuated to study the impact of high drug, low NaCl content on
ygroscopic growth proﬁles. In this study phase, two tobramycin
ormulations are compared. The ﬁrstmodel formulation (TOB) con-
ists of a 75mg/mL tobramycin solution (160mM) with no NaCl
ontent and is loosely based on the commercial product Bramitob©
Chiesi; containing 75mg/mL tobramycin). The TOB formulation
epresents a solution in which the drug content is sufﬁciently high
o ensure isotonicity without the need for NaCl as a tonicity reg-
lating excipient. A second model formulation (TOB+NaCl; based
n the commercial product, Tobi©, Novartis) contains 60mg/mL
obramycin (128mM), 2.25mg/mL NaCl (39mM), and a small
mount of sulfuric acid to adjust the pH to 5.5–6.5 (ﬁnal tonic-
ty: 166mM). Model formulations, rather than their commercial
ounterparts, are intentionally compared to generate highly accu-
atemodels of hygroscopic growthwhich rely on knowledge of the
xactmass composition of each formulation and to better compare
he impact of no NaCl vs. small amounts of NaCl on hygroscopic
rowth of high dose nebulizer solutions.
. Materials and methods
.1. Humidity in a nebulized airﬂow as a function of airﬂow rate
nd geometry of mixing
Theexperimental setupof the apparatusused tomeasure theRH
ithin a nebulized airﬂow is shown in Fig. 2A. The ultrasonic nebu-
izer (Omron, NE-U07)was set to amaximumﬂow rate throughout.
he airﬂow rates through the systemwere set using multiple mass
ow controllers (MKS Instruments). The ﬂow rate to vacuum was
et to the cumulative ﬂow rates or airﬂows (1) and (2). Once
he ﬂow rates of the various airﬂows were set (ranging between
mL/min and 5000mL/min), time was given for the humidity to
each equilibrium before the measurement was taken. Note that
hen nebulizers are used to administer medication, time is not
iven to reach equilibrium. Only deionized water was nebulized
n this study to avoid contamination of the probes and subse-
uent buffering in time response. Thus, the RH measured with this
ethodwill behigher than those experienced if thenebulized solu-
ion contained a solute, such as saline; the presence of a solute
ould reduce the amount of water that would be partitioned to
he gas phase.
.2. Nebulizer solutions
A commercially available sterile saline product (Steri-Neb®,
.9%, w/v) was used. Breath® (salbutamol 5mg/2.5mL nebulizer
olution) and Flixotide® Nebules (Allen & Hanburys Ltd., Uxbridge,
K; 0.25mg/mL) were sourced from the manufacturer and used
ithout dilution. While the Breath® formulation contains only
albutamol sulfate and NaCl (equating to a total solids concen-
ration of 1.0% (w/v)), the Flixotide® Nebules formulation also
ontained undisclosed amounts of polysorbate 20, sorbitanlaurate,
onosodium phosphate dehydrate, dibasic phosphate anhydrous,
nd NaCl in addition to the disclosed drug concentration, pre-
luding calculation of the total solids concentration (%, w/v).
obramycin powder was purchased from Sigma–Aldrich and dis-
olved either in water to produce ﬁnal tobramycin concentrations
f 75mg/mL (equivalent to Bramitob© (Chiesi) without the saline)
r in 2.25mg/mL NaCl solution at a tobramycin concentration of
0mg/mL (equivalent to Tobi© (Novartis)), before the pH of the
olution was reduced to ∼6 with dilute sulfuric acid.associatedwith the expectedRH fromvariations in themass ofwater nebulized over
time. (For interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of the article.)
2.3. Single aerosol droplet analysis
Three complementary single particle analytical techniques, a
double-ring electrodynamic balance (EDB), comparative kinetic
EDB (CKEDB), and optical tweezers (OTs), were used in this study.
The EDBwas used tomeasure the thermodynamic equilibrium size
of droplets across a wide range of RH (from near saturation to dry)
for droplets >5m in diameter. OTs and the CKEDB were used to
investigate the dynamic size changes experienced by droplets due
to rapid changes in conditions. Droplets between 3 and 8m in
diameter were probed in the OT while droplets ranging from 6m
to ∼50mwere studied in the CKEDB. Amodel based on the semi-
analytical mass ﬂux equations of Kulmala et al. (1993) was used to
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nterpret and parameterize the kinetic data obtained through both
xperimental techniques, allowing simulation of aerosol dynamics
nder physiologically relevant conditions for particle sizes typical
f inhalation therapies.
A detailed description of the experimental setup and operation
f the EDB has been published previously (Haddrell et al., 2012;
argreaves et al., 2010) and only a brief overview will be given
ere. A starting solution/suspension was placed into the reservoir
f a droplet-on-demand dispenser (Microfab, MJ-ABP-01with an
riﬁceof30m)thatwaspositioned4mmabovean inductionelec-
rode. Thepresenceof thehighvoltage inductionelectrode (+500V)
nduced a mirror charge on the droplet resulting in a net negative
harge of <50 fC on the droplet as it was ejected from the dispenser.
he net charge on the droplet allowed it to be manipulated by the
lectric ﬁeld in the EDB, which was generated through application
f a 2kV0-P, 100Hz signal to two ring electrodes. A DC offset volt-
ge to the AC ﬁeld was required to maintain the position of the
roplet at the null point of the trap (VDC). The mass growth factor
f the droplet is reported as the VDC at a given RH divided by VDC of
he equivalent dry particle devoid of water at the null point when
nder dry conditions (RH<10%). The absolute size of the droplet
as measured by taking the angular spacing between fringes in
he elastic scattering pattern and a geometrical optics approxima-
ionwas used to estimate the radius (Haddrell et al., 2012). The VDC
nd radiusweremeasured continuously as thehumiditywas varied
rom high humidity (>85%) to low humidity (<30%) in a stepwise
ashion over a 40h period; the RHwas changed in steps of 10% and,
t a minimum, an hour was allowed for the whole EDB chamber
nd particle to equilibrate at each step.
A detailed description of the setup and operation of the CKEDB
as been published previously (Davies et al., 2012b; Davies et al.,
013), and only a brief overview will be given here. The CKEDB has
any characteristics similar to that of the EDB, most notably the
ethod of generating a dropletwith net charge. The primary differ-
nce between the two devices is the orientation of the electrodes
herein the CKEDB has two concentric cylindrical electrodes con-
isting of an outer grounded electrode and an inner electrode with
variable potential of 0–1kV0-P, (100–500)Hz. This electric ﬁeld
rovides a much stronger trapping potential for conﬁnement of
he aerosol particle than the ring electrode EDB and allows droplets
o be conﬁned within 100ms from their initial creation at the tip
f the dispenser. A trapped droplet was imaged and the size esti-
ated in the same way as the EDB, using the angular variation in
he intensity of the elastically scattered light and the geometri-
al optics approximation. The radius of the droplet was measured
ith a time resolution of 10msuntil either the particle size reached
quilibrium or the particle became too small to remain trapped.
A detailed description of the setup and operation of the optical
weezers has been published previously, and only a brief overview
ill be given here (Reid et al., 2011). Using an ultrasonic nebulizer
Schill Medical, Aerosonic Travel), a population of saline droplets
as dispersed into a trapping cell where a single droplet 3–8m
n radius was captured in the focal point of a laser beam (532nm,
pus). The high numerical aperture objective used to form the
rap was also used to collect the elastic and inelastically scattered
ight emitted from the trapped droplet. The diameter of the droplet
as measured by comparing the resonant ﬁngerprints of the whis-
ering gallery modes (WGMs) wavelengths in the Raman band
ith predictions from Mie scattering theory. Through the use of
beam splitter and a mechanical shutter, modulation of the laser
ight intensity illuminating the droplet was used to induce small
hanges (∼10mK) in the droplet temperature (Miles et al., 2010).
hese small changes in temperature led to the sequential evapo-
ation and condensation of water on the droplet, the kinetics of
hich were recorded bymeasuring the change in droplet size with
ub-nanometer accuracy and with a time resolution of <100ms.f Pharmaceutics 463 (2014) 50–61 53
Previously, we have shown that suchmeasurements can allow pre-
cise measurements of the kinetics of water transport to or from
aerosol particles (Miles et al., 2010).
2.4. Modeling of hygroscopic aerosol growth during inhalation
Experimental data were supported by a number of model sim-
ulations to describe both the equilibrium and dynamic response of
the aerosol. The equilibriummodels, used primarily for saline solu-
tion, included both the extended aerosol inorganic model (E-AIM)
(Clegg et al., 1998), the aerosol diameter dependent equilibrium
model (ADDEM)and theClegg/Wexler treatment (Clegget al., 1997,
1998). These treatmentswere used both to directly compare exper-
imental thermodynamic growth data with theory, as well as to
determine the water activity/mass fraction of solute relationships
required for use in the mass ﬂux equations, based on the semi-
analytical solution to the mass and heat ﬂux equations of Kulmala
et al. (1993). The semi-analytic equation was used to simulate the
dynamic responseofdroplets to changes in conditions (e.g.a change
in RH), such as those imposed on droplets in the OT and CKEDB. The
useof thismodel asameansof simulatingdata in theseexperiments
has been discussed and veriﬁed in detail by Miles et al. (2010) and
Davies et al. (2012a,b), and for brevity will not be described here.
Although it is not possible at this stage to directly replicate the very
high humidities and elevated temperature of the respiratory tract
experimentally, the measurements are designed to characterize
the equilibrium growth and kinetics of evaporation/condensation
over a wide range of conditions, validating the model and provid-
ing empirically-derived parameters to achieve robust predictions
of the growth dynamics to be expected under the relative humidity
condition during inhalation.
3. Results
3.1. Humidity in a nebulizer airﬂow as a function of nebulizer
orientation
In order topredict theRHwithin anebulizer airﬂowasa function
of ambient RH and device construction (e.g. diameter and location
of the T-junction), the amount of water nebulized was ﬁrst mea-
sured as a function of the airﬂow by weighing the mass of water in
the reservoir of the nebulizer before and after a set period of time
of nebulization. While the amount of water nebulized as a func-
tion of time was found to be dependent on the airﬂow rate, the
overall mass of water in the gas/aerosol phase per unit volumewas
found to be independent of the airﬂow rate. The mass of water in a
given volume of air was 7.9±2.3 times that expected based on the
saturation pressure of water (the majority of which will be in the
condensed particle phase) independent of airﬂow rate.
Estimates of the expected RH of the vapor ﬂow emitted from a
standard nebulizer as a function of the secondary airﬂow rate and
RHwere based solely on themass ofwater emitted by the nebulizer
(Fig. 2B). These predictions assume that full mixing occurs and is
controlled strictly by the two airﬂow rates. Given that the breath-
ing rate of a healthy person ranges between 0 and ∼20L/min at any
point in time, the predictions in Fig. 2B suggest that the humidity
in an inhaled airﬂow will be saturated regardless of the ambient
air RH in ﬂow 2 and the relative ﬂow rates 1 and 2. However, this
was found not to be the case whenmeasured (Fig. 2C). When a sec-
ondary airﬂowwas added through a T-junction, the humidity of the
airﬂow downstream of the T-junction followed a similar trend as
those predicted in Fig. 2B, but at much lower total ﬂow rates with
values that are readily achieved during inhalation. This is likely due
to the air pressure exerted by the pump rather than the airﬂow rate,
a scenario that is also likely to be applicable on inhalation. Even
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hough the airﬂow through commercial constant output nebuliz-
rs is typically set to the average breathing rate of 6 L/min, the air
ressure at the mouthpiece is very low (measured to be <0.014psi
or the device used in this study). As a result, any incursion of the
econdary airﬂow as a result of this pressure drop will dramati-
ally affect the RH at the point of inhalation, as will the orientation
f the airﬂows in the device (e.g. the diameter of the opening of the
-junction). To verify this, the values of all airﬂows in the system
ere controlled and the RH was measured. In this situation, the
bility to predict the RH at the point of inhalation based solely on
he mass of water nebulized was possible (Fig. 2D).
Taken together, thework presented here, coupledwith previous
tudies (Krajnik et al., 2009;Nerbrink et al., 2003; Zhou et al., 2005),
learly demonstrates that aerosol produced from a nebulizer can
each a wide range of RH, even extending below 50%. The extent
f the range is dependent on the construction of the nebulizer, the
mbient RH, and the airﬂow rates (ratio of Airﬂow (1) to Airﬂow
2), see Fig. 1) through the device. Thus, a detailed understanding
f the hygroscopic behavior of nebulized aerosol will be needed to
ccurately model their deposition in the lung.
.2. Single aerosol droplet analysis of low dose nebulizer solutions
To maintain the osmotic potential at the surface of the lung
uring inhalation, nebulizer solutions typically consist of a saline
olution with the drug and, in certain cases, other additives. To
eparate out the role of the saline from that of the drug and addi-
ives, the thermodynamic and kinetic hygroscopic properties of
aline were ﬁrst measured. The equilibrium state mass and radial
rowth factors of saline droplets (the droplet size relative to the
ize of a dry particle composed entirely of the salt) were deter-
ined using the EDB (Fig. 3A and B), and were found to agree
ith well-established models (E-AIM). The time dependence of
he size of a series of droplets evaporating from initially dilute
olutions into ∼0%, ∼50% and ∼90% RH in the CKEDB are shown
s averaged single time-dependencies in Fig. 3C. The kinetic mass
ux equations, incorporating the Clegg/Wexler treatment of water
ctivity and density, were used to predict the temporal variation in
roplet size under the experimental conditions. The time to reach
he equilibriumdroplet sizewas observed to dependon the relative
umidity, and the predicted and measured trends for evaporation
nd condensation were consistent within the uncertainties of the
xperiment and simulations. These results are consistent with our
revious reported studies for aqueous NaCl solution aerosol (Miles
t al., 2010).
In both the double-ring and CKEDBs, the droplets studied were
6m in diameter, a size range that does not entirely overlap
ith the inhalable aerosols produced by jet nebulizers, which
roduces aerosol droplet diameters that typically span 0.5–10m
Kwong et al., 2000) with median values usually ranging from 2
o 7m, depending on nebulizer type and formulation properties
Mccallion et al., 1995). Of note, is that nebulized aerosol droplets
re frequently undersized due to evaporation under the ambient
nvironmental conditions at which measurements are typically
erformed. Further, the measurements made by the EDBs only
ccess RHs as high as ∼90%, again not directly representative of the
H observed in the respiratory tract. OTs were therefore used to
alidate themodel treatment for the condensational growth kinet-
cs of saline aerosol droplets in a size regime closer to that expected
rom a medical nebulizer (<8m diameter) and at an RH closer to
hat representativeof the respiratory tract (>95%RH). Following the
rocedure adopted in our previous work (Miles et al., 2010), the
eturn of the droplet to an equilibrium size by condensational
rowth was monitored following a transient perturbation in vapor
ressure induced by a small change in temperature. An example of
uch a transient growth event at very high RH is shown in Fig. 3D.f Pharmaceutics 463 (2014) 50–61
The same mass ﬂux equations with the same parameterizations
for water activity/mass fraction of solute were used for both size
regimes and over the full range of RH conditions, conﬁrming
that the model is capable of predicting the dynamic response of
droplets across broad size and RH ranges, and for both evaporation
and condensation. Furthermore, the importance of including a
correction for the slow heat ﬂux by collisions with gas phase
nitrogen/oxygen molecules is clear. Although the actual growth
of the droplet was low (Fig. 3D), the consequence of neglecting
this correction is evident from the under-prediction of the time to
reach equilibrium if heat transport is ignored. Failure to correct for
heat ﬂux underestimated the time to reach equilibrium by ∼2 s,
thereby demonstrating the need for accurate measurements of
growth rates to support deposition modeling, rather than assum-
ing equilibrium conditions. Indeed, for the droplet sizes typical of
inhalation, the rate of mass ﬂux is largely controlled by the ﬂux of
heat back into the gas phase rather than the diffusional transport
of mass. Neglecting the limitations imposed on the growth rate
by the slow heat conduction away from the droplet leads to a
signiﬁcant over-prediction of the growth rate.
Most commercial nebulizer formulations of salbutamol sul-
fate are simple two component systems containing saline and the
soluble drug. The thermodynamic hygroscopic properties of the
Breath® formulation, obtained in the same manner as pure saline,
are shown in Fig. 4A and B, reporting both the relative mass and
radial growth with RH. The dissolved solids content of the formu-
lation was calculated to be 1.0% (w/w), of which NaCl comprised
81% (w/w) and salbutamol sulfate comprised only 19% (w/w). It
is therefore not surprising to see that the equilibrium hygroscopic
growth curve (i.e. the relative radial growth factors) was similar
in form (distinct efﬂorescence and deliquescence points) to that of
saline but with a signiﬁcant suppression in the growth due to the
presence of less hygroscopic salbutamol sulfate (Fig. 4A). This is at
oddswith previous studieswhich have suggested that the behavior
of a similar compound, isoproterenol hydrochloride, was identical
to NaCl aerosols (Martonen et al., 1982). The CKEDBmeasurements
of the time-dependence indroplet size during evaporation fromthe
droplet as a functionof humidity are shown in Fig. 4C. A comparison
of Figs. 3C and 4C shows a minimal difference between evapora-
tion proﬁles for RH values 50% and lower, indicating no signiﬁcant
impact of the drug mass on the evaporation kinetics and no alter-
ation of phase behavior, such as would be observed if a glass or gel
were formed by the organic components (Bones et al., 2012).
The thermodynamic properties of Flixotide® Nebules formu-
lation are shown in Fig. 4D and E. Like Breath®, the Flixotide®
Nebules formulation had distinct efﬂorescence and deliquescence
points, likely due to the NaCl in the formulation, with a slight
reduction in hygroscopic growth factor due to the presence of non-
hygroscopic components. Based on the magnitude of reduction in
mass growth factor across all RH, the weight percent (w/w) of NaCl
out of the total mass of dissolved solids may be estimated to be
below 50%, indicating a signiﬁcant proportion of the solute mass
likely consists of the additional excipients. Fluticasone propionate
is insoluble inwater. Thus, the Flixotide® Nebules formulation con-
sists of a multi-component system containing not only saline and
the active ingredient, but also an undisclosed amount of several
other excipients used to stabilize the active ingredient in the sus-
pension. This missing information prevents the calculation of the
exact mass fractions present in the formulation, as well as the rel-
ative contributions to hygroscopicity of each component. CKEDB
measurements of the evaporation kinetics upon injecting droplets
into various humidities are shown in Fig. 4F. As with the salbuta-
mol sulfate formulation, droplets from Flixotide® Nebules showed
behavior similar to salinedroplets, the evaporation ratewas limited
by gas phase diffusional transport of water away from the droplet
and heat to the droplet surface.
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Fig. 3. Equilibrium state mass (A) and radial (B) growth factors of saline as a function of RH, as measured with the EDB. The deliquescence/efﬂorescence cycle is clear in (A),
while (B) reports measurements of the relative size change for solution droplets at RHs above the efﬂorescence RH. (C) The time-dependence of the size of saline aerosol
droplets injected into an air ﬂowwith relative humidity of 90%(right curve), 50% (mid curve) and <10% (dry air; left curve), asmeasuredwith the CKEDB. The red line indicates
the model prediction while the gray bar indicates error associated with the model due to the uncertainty in the RH (±1%). At 50% and 90% RH, the evaporating droplets reach
an equilibrium size. (D) The time-dependence of the radius of a saline droplet during condensational growth from an initial state to a ﬁnal equilibrium state, as measured
w ated b
c eader
i
k
t
r
p
e
f
m
a
ﬂ
s
b
e
m
d
e
b
(
i
m
s
w
t
h
t
b
a
t
tith OT. The experimental data are indicated by circles. Model predictions are indic
omparison. (For interpretation of the references to color in this ﬁgure legend, the r
The semi-analytical treatment for calculating themass ﬂux dur-
ng evaporation or condensation at any moment in time requires
nowledge of the variation of the water activity (equivalent to
he vapor pressure of water) with mass-fraction of solute. This is
equired in order to calculate the concentration gradient in the gas
hase. The concentration gradient can be calculated from knowl-
dge of the gas phase RH and droplet water activity, derived either
rom thermodynamic models or from equilibrium hygroscopicity
easurements (i.e. the radial growth factors from Figs. 3B and 4B
nd E). From the semi-analytic treatment, the instantaneous mass
ux is calculated and, thus, the mass loss/gain over a short time
tep. The new droplet radius at the end of this time step must then
e calculated to once again use the radial growth factor data to
stimate the new diffusional gradient in the gas phase and the
ass loss in the next time step. This requires knowledge of the
ensity of the aerosol droplet with varying composition across the
ntire range of water activity (i.e. RH%). Solution densities cannot
emeasured over the full RH range frombulk phasemeasurements
solute concentrations are typically well above the solubility lim-
ts below 80% RH) and must instead be determined from aerosol
easurements. To estimate the density of a solution, it is neces-
ary to know both the wet and dry diameters of the aerosol as
ell as the mass of the solution droplet relative to the dry par-
icle. When the fraction of NaCl in the total solids mass (%w/w) is
igh, the aerosol has a deﬁned efﬂorescence point that results in
he formation of a non-spherical particle whose diameter cannot
emeasured by light scattering. Thus, for both commercially avail-
ble salbutamol sulfate and ﬂuticasone propionate formulations,
he low concentration of the drug in the saline solution affects
he radial growth factor but not the efﬂorescence point, and they lines, with the inﬂuence of latent heat included(red) and not included (black) for
is referred to the web version of the article.)
absolute dry diameter and thus solution density cannot be deter-
mined. This precludes a fully robust simulation of the evaporation
kinetics, a potentially signiﬁcant limitation when examining evap-
oration to low RH and preventing direct comparison with a model
in Fig. 4C and E. The evaporation curves are, however, qualitatively
very similar and occur over similar timescales to the evaporation
of saline droplets. For the extremely high RHs (>95%) for which the
simulations are applied to predict growth in the respiratory tract
later in the paper, assuming that the density is equal to that of the
saline solution (approximately the same as water) introduces only
negligible error.
3.3. Single aerosol droplet analysis of high dose nebulizer
solutions
Tobramycin solutionswere chosen as an appropriatemodel sys-
tem to investigate the impact of high dose drug solutions and low
NaCl content on hygroscopic growth proﬁles. As mentioned above,
in order to accurately model aerosol dynamics, the absolute chem-
ical composition of the starting formulation must be known to a
high degree of certainty. Although the composition of the com-
mercial formulations of Tobi© is readily available, an issue arises
when the pH of the commercially available solution is pH adjusted.
This results in a slight change in the concentration of all the solutes
in the starting formulation. As a result, the ability to accurately
model, to a very high degree of certainty, the rate and magnitude
ofmass ﬂux derived from the hygroscopic growthmeasurements is
notpossible. To address this, TOBandTOB+NaCl formulationswere
prepared from the bulk, where the precise chemical composition
of the starting formulation was known.
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Fig. 4. Evaluation of two low dose commercial nebulizer preparations: salbutamol sulfate (left panel) and ﬂuticasone propionate (right panel). Mass (A and D) and radial (B
and E) growth factors of aerosol droplets as a function of RH, as measured with the double ring EDB. The solid lines in A and D indicate the mass growth curve for pure saline.
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dry air; left curve) as a function of time (measured with the CKEDB). OT measurem
egarding dissolved excipient mass in these commercial preparations prevented co
Themass and radial growth factors as a functionofRHare shown
n Fig. 5A and B for TOB and Fig. 5D and E for TOB+NaCl. Droplets
f these formulations were injected into three different relative
umidities and the mass ﬂux measured, as depicted in Fig. 5C for
OB and 5F for TOB+NaCl. Similar to the three previous formula-
ions, the evaporation kinetics were limited by gas phase diffusion
or TOB across all RHs. Kinetic limitations in the rate of evaporation
as observed when TOB+NaCl was injected into an airﬂow of 50%
H, as evidenced by the continual loss of water from ∼4 to ∼8 s.
his suggests the formation of an amorphous state or the presence
f surface active species.
Unlike the salbutamol sulfate andﬂuticasonepropionate formu-
ations, deliquescence and efﬂorescence points were not observed
or the TOB and TOB+NaCl formulations. Thus, it was possible to
ollect accurate radial data down to low RH for both (Fig. 5B and
), to determine the dry radii and, hence, growth factor across a
ide range ofwater activities (Fig. 6A and C). From such a completean air ﬂow with relative humidity of 90% (right curve), 50% (mid curve) and <10%
f condensational growth were not performed, as the lack of disclosed information
tion of the growth model.
picture of the thermodynamic properties and densities, the kinet-
ics of water evaporation and condensation using the semi-analytic
treatment can be fully predicted to a high degree of certainty
(Fig. 6B and D). Remarkably good agreement with the experimen-
tal measurements was observed for the relative humidity region
in which growth factors were determined, well within the uncer-
tainty associated with the relative humidity, which was by far the
largest uncertainty present in the simulation. Again, evidence of
the formation of the amorphous state is observed for the TOB+NaCl
formulation in Fig. 6D, where the experimental data deviates from
the model prediction between ∼4 and ∼8 s.
3.4. Modeling of hygroscopic aerosol growth during inhalation
using experimentally-determined growth factors
The ability to use the measured relative mass, radial growth
factor, and density of the aerosol at equilibrium as a function of
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Fig. 5. Mass (A and D) and radial (B and E) growth factors of TOB and TOB+NaCl aerosol droplets as a function of RH, as measured with the double ring EDB. The solid line in
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he aerosol droplets injected into an air ﬂow with relative humidity of 90% (black c
measured with a CKEDB).
ater activity and composition, and to predict the independent
xperimental mass ﬂux measurements collected with the CKEDB
emonstrates the high degree of understanding achieved for
he high dose solution systems. Thus, accurate predictions can
e made of mass ﬂux in dynamic environments, such as that
xperienced by an aerosol during inhalation. To highlight the
otential use of these mass ﬂux simulations, the kinetics of aerosol
vaporation/condensation were compared for the TOB, TOB+NaCl
nd saline aerosols (Fig. 7) in response to very subtle increases in
H at high humidity (i.e. elevation from98 to 99.5% RH). These con-
itionsmight reﬂect a hypothetical scenario inwhich the humidity
ithin a given nebulizer remains nearly saturated at ∼98% RH
nd the generated aerosol travels rapidly through the device prior
o entering the higher humidity environment of the respiratory
ract. Fig. 7A depicts the extent of aerosol size change when a new
roplet of saline (aw of 0.995) with a diameter ∼5m is generated
nd held at 98% RH for 5 s (undergoing evaporation) prior to rapidE are extrapolations of the radial growth factor. (C and F) The time dependence of
), 50% (dark gray curves) and <10% (dry air; light gray curves) as a function of time
elevation of the RH to 99.5%, whereby condensational growth
commences. Fig. 7B shows the same aerosol droplet injected into
and held at 98% RH for 1s prior to elevation of RH to 99.5%. In
this case, evaporation time is signiﬁcantly decreased and thus the
magnitude of condensational growth in 99.5%RH is reduced. Fig. 7C
depicts the same scenario, except that the initial period of droplet
residence at 98% is reduced to 0.5 s, resulting in a further signif-
icant decrease in droplet evaporation and a swift achievement of
equilibrium size after condensation growth at 99.5% RH. Note that
for a saline droplet with a starting diameter of 5m, its size is
never the same as the tobramycin containing droplets at any point
in time; this further demonstrates the problems associated with
indiscriminant use of saline as amodel system to predict the hygro-
scopic growth of nebulized aerosols during inhalation, especially
when formulations contain low or no NaCl content. As a case in
point, the TOB+NaCl formulation studied here behaves hygroscop-
icallymuchmore like the TOB formulation than the saline solution.
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Fig. 6. Density as a function of RH (A, C) of TOB and TOB+NaCl, the changes to the radius of this aerosol following its injection into an air ﬂow with a RH of ∼80%and ∼55%
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oere modeled (B, D). In B and D, the black line indicates the model prediction while
ith the RH (±1%).
It has previously been suggested that coarse droplets (>1m)
o not reach equilibrium during lung residence times of 5 s
Broday and Georgopoulos, 2001). However, the availability of
mpirically-derived growth factors from the current work shows
hat equilibrium size may actually occur during relevant time
eriods for coarse aerosols although it depends on the RH trajec-
oryexperiencedby theaerosol andon the ‘coupling’ of total aerosol
urface area for condensation to water mass available in the lungs
o condense. For the tobramycin solution droplets, less evapora-
ion is predicted to occur over the same time frame at 98% RH
ompared to the saline droplets. Further, condensational growth
ccurring at 99.5%was attenuated for both TOB and TOB+NaCl. The
bility to accurately predict changes to droplet sizes in response to
oth subtle andprofound changes in humiditymayhave the poten-
ial to signiﬁcantly improve in silico models of aerosol deposition,
uch as computational ﬂuid dynamic models (Forbes et al., 2011).
lso, a greater understanding of how the formulation of high dose
on-hygroscopic drug compounds or NaCl content inﬂuences the
hanges to droplet size during nebulization and inhalation, may
nform rational formulation strategies for nebulizer products in the
uture (Haddrell et al., 2013).
Further evidence of the deﬁciencies of non-discriminant appli-
ation of saline growth rates to all nebulizer formulations to
pproximate dynamic changes to droplet size is highlighted in
ig. 8A. This simulation depicts the simpliﬁed scenario of what
ould happen to three equally sized droplets (2.0m diameter
t an RH of 50% prior to inhalation) containing the formulations
aline, TOB and TOB+NaCl. Note that for the aerosol droplets to
ave an identical diameter at a given humidity, the weight percent
f NaCl in the solute of the saline droplet will always be lower dueay area indicates the error of the model resulting from the uncertainties associated
to the highly hygroscopic nature of NaCl. The kinetic growth pro-
ﬁles of these identically sized droplets as they enter an area of high
humidity (i.e. the mouth and respiratory tract) demonstrate that
the saline droplet has a larger magnitude of mass ﬂux than the less
hygroscopic tobramycin solutions, i.e. saline droplets will experi-
ence greater hygroscopic growth in the respiratory tract compared
to non-hygroscopic formulations, such as the high dose TOB and
TOB+NaCl solutions. The disparity grows as the time spent in the
respiratory system increases (Fig. 8B). Along with Fig. 7, these data
demonstrate that general predictions of drug deposition in the lung
based on a salinemodel are questionable. Further, non-hygroscopic
formulations may have the potential for greater peripheral lung
deposition due to their relative lack of hygroscopic growth in the
respiratory tract.
4. Discussion
Aerosol growth during inhalation is dependent on the availabil-
ity of water vapor in the lung, and may be limited by the high
particle count in a nebulized aerosol. Beyond the sheer number
of droplets within the airﬂow, the composition, initial size, and RH
the droplets experience immediately prior to inhalation will also
play a major role in reducing aerosol growth during inhalation.
The threshold number concentration of saline particles present in a
nebulized aerosol whose hygroscopic growthwill be limited by the
availability of water vapor in the lung as a function of the aerosol
median diameter immediately prior to inhalation is estimated in
Fig. 9. These estimations are based on the total mass of water vapor
in the lung (Nerbrink et al., 2003) and the total mass of water
required for thegrowthof the entirepopulationof salinedroplets of
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Fig. 7. Model prediction of the time-dependence in the radius of an aerosol consist-
ing of TOB, TOB+NaCl, and saline in response to very subtle changes in RH (thick
black line) with all droplets initially 2.5m in radius when generated. (A) Depicts
a hypothetical scenario in which the nebulizer RH is 98% and the droplet residence
time in the nebulizer is 5 s after which inhalation increases the RH to 99.5%. Exhala-
tion is not depicted. (B and C) depict the same scenario as described above, but the
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Fig. 8. (A) Growth of pure saline, TOB and TOB+NaCl droplets with an identical
starting radius at 1m and equal water activity (equivalent to equilibrium at 50%
RH) injected into an atmosphere of 99.5% RH. (B) The difference between the radii
of the saline droplet and that of a droplet with the same starting radius made up of
the drug shown in (A).
Fig. 9. The concentration of inhaled droplets with a given aerosol median diameter
whose growth during inhalation will be limited by the availability of water vapor
present in the lung. When the aerosol concentration is above the appropriate line
the aerosol growthwill be controlled by the availablemass ofwater in the gas phase.
When the aerosol concentration is below the line the aerosol growth should beunaf-
fected. Line color indicates the RH the population of the aerosol was equilibrated
with immediately prior to inhalation. The data points are the number concentra-roplet residence time in the nebulizer at 98% RH has been decreased to 1 and 0.5 s,
espectively.
given starting size. Generally speaking, when particle concentra-
ions are above the line, water availability will determine the rate
nd magnitude of mass ﬂux during inhalation; when particle con-
entrations arebelow the line there is theoretically enoughwater in
he vapor phase in the lung to sustain the degree of aerosol growth
uring inhalation expected from the solution thermodynamics.
The droplet number concentration produced by a series of com-
ercially available nebulizers was calculated based on the data
eported by Reisner et al. (2001) and is also shown in Fig. 9. For all
f the nebulizers shown, there is expected to be sufﬁcient water to
ccount for the growth of the aerosol in the nebulized airﬂowwhen
he RH prior to inhalation is at 98%. This results from less water
eing required for the hygroscopic growth of the saline present at
n RH of 98%. This means that the predictions of aerosol growth
hown in Fig. 7 are applicable to commercially available nebulizers
tion and aerosol median diameter for a series of commercial nebulizers, and were
estimated from data published previously (Reisner et al., 2001).
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nd, as a result, indiscriminant application of saline growth proﬁles
o estimate the behavior of non-hygroscopic solutions, such as the
obramycin formulations studied here, will lead to over-prediction
f droplet growth in inhalation models.
In the estimation presented in Fig. 9, the assumption is made
hat the mass of water in the vapor phase is ﬁnite. In the lung
owever, with its large surface area, warm temperature and moist
urfaces, any reduction in the mass of water in the vapor phase
hrough uptake by an aerosolmay be replenished by the lung itself.
or this reason, the estimations made in Fig. 9 are likely an over-
stimation of the importance of droplet count on limiting aerosol
rowth, and in reality all of the lines should likely be moved up.
How the magnitude of overall mass ﬂux of an aerosol during
nhalation results in changes in the total and regional doses have
een modeled previously (Asgharian, 2004; Mitsakou et al., 2005).
ithin these models, hygroscopic growth was found to have a
arge effect where the minimum in the total deposition fraction
f hygroscopic aerosol range between 500 and 800nm while the
inimum for the hydrophobic aerosol centered around 100nm.
iven that the median aerodynamic diameter of nebulized thera-
eutic aerosols is around 2m (Reisner et al., 2001), only a slight
ifference in total deposited dose would be expected. However,
he pattern of deposition would be expected to differ signiﬁcantly,
herein aerosols with a high saline content (i.e. low dose formu-
ations) may show a higher proportion of upper airway deposition,
hile aerosols with a lower hygroscopicity (i.e. high dose formula-
ions with little to no NaCl) may exhibit greater peripheral depo-
ition. The degree to which this shift in deposition site occurs as a
esult of the size change measured in this study (Fig. 8) is unclear
t this time, and requires detailed modelling to explore further.
. Conclusions
The ability to accurately model the aerodynamic diameter of
n aerosol following its transition between airﬂows of various RH
as been demonstrated. This then allows the kinetics of aerosol
vaporation/condensation proﬁles to be modeled for a variety
f pharmaceutically relevant inhalation scenarios, during which
erosol residence in the device, for example, can vary dramatically.
ith the increasing variety of nebulization formats and device
esigns (e.g. traditional jet nebulizers connected either through
ubing to face masks or directly to the mouthpiece, aerosol deliv-
ry during mechanical ventilation, discrete hand-held nebulizers,
reath-actuated devices and slowmist formats (Watts et al., 2008))
his model is of great relevance.
Through comparison of pharmaceutically relevant formula-
ions, this study has demonstrated that the inclusion of high dose,
on-hygroscopic drugs or decrease in NaCl additives can signiﬁ-
antly change the equilibrium hygroscopic response of the aerosol
nd can alter droplet evaporation and growth kinetics during an
nhalation event. Thus, overall, the model developed in this study
ay be very valuable in enhancing in silicomodels of pharmaceuti-
al aerosol deposition in the lung, especially if combinedwithmore
ccurate patient inspiratory breathing proﬁles. Further, the results
f this study deepen our understanding of dynamic changes to
roplet sizeduring thenebulizationprocess itself andare adaptable
o a wide range of nebulization formats. Finally, a greater under-
tanding of how formulation parameters inﬂuence the kinetics of
roplet evaporation/condensation during a real time inhalation
yclewill inform rational formulation strategies for nebulizer solu-
ions in the future. Adaptation of the EDB and OT technology to
easure dynamic changes in propellant-containing pressurized
etered dose inhaler formulations aswell as dry powders formula-
ions to explore the impact of real time humidity changes on these
ystems is currently under way. The results of these future stud-
es promise to enhance our understanding of, as well as enablef Pharmaceutics 463 (2014) 50–61
us to more accurately predict and manipulate, drug deposition of
pharmaceutical aerosols in the lung.
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